The observed capability of trodusquemine to enhance whole-body insulin sensitivity and counteract mechanisms linked to hepatic steatosis attracted interest in further investigating the potential of this compound for the treatment of metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), which is frequently coexistent with T2DM and obesity. This evidence concerns the gene INS and type 2 diabetes mellitus.